Market Overview

Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

Share:
Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

Benzinga recently had the chance to chat with Jason Napodano, biopharma analyst and consultant, owner of BioNap Consulting and former biotech analyst at Zacks. Below are just a few of the expert’s comments on potential M&A activity and partnerships in the biotech segment in the current market, in addition to a brief comment on women's health.

Potential M&A Activity

When asked about the potential M&A activity in biotech in the current market and macro environment, the analyst explained that biotech companies use each other’s shares as currency.

For instance, if Juno Therapeutics Inc (NASDAQ: JUNO) was down 50 percent from months ago and Celgene Corporation (NASDAQ: CELG) made a deal for 30 percent premium, investors would be disturbed, he expounded.

Related Link: Jason Napodano On His Approach To Biotech & Current Market Conditions

That being said, Napodano noted it is a common misconception that biotech M&A deals are completed during selloffs and bear markets. Quite the opposite: the analyst believes it is more likely for these deals to occur in bull markets.

Partnerships And Biotech

Partnerships are fundamental for biotech companies, especially during development stages. When questioned about them, Napodano said partnerships are more attractive than outright M&A deals, noting that can be particularly beneficial for small companies in terms of funding.

The basic idea here is that “50 percent of something is better than 100 percent of nothing.”

Women’s Health

Finally, the expert was prompted on women's health in general and endometriosis and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in particular.

Regarding this subject, he commented that endometriosis' current treatments, like Lupron, are actually cancer drugs that aren't specifically designed for endometriosis.

Consequently, Neurocrine can specialize and take advantage of developing a drug specifically designed to treat endometriosis, as opposed to bigger biotech firms that may pass on the opportunity.

Image Credit: Public Domain

Latest Ratings for JUNO

DateFirmActionFromTo
Jan 2018Standpoint ResearchDowngradesBuyHold
Jan 2018BarclaysDowngradesOverweightEqual-Weight
Jan 2018Maxim GroupDowngradesBuyHold

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

 

Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Posted-In: BioNap ConsultingAnalyst Color Biotech Long Ideas Exclusives Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
CYBBFCitigroupDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com